Detalhe da pesquisa
1.
NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines.
Cell
; 175(7): 1744-1755.e15, 2018 12 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-30503208
2.
Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells.
Cell
; 175(7): 1731-1743.e13, 2018 12 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-30503213
3.
Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis.
Nature
; 588(7836): 146-150, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32726800
4.
Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies.
Blood
; 123(5): 678-86, 2014 Jan 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-24326534
5.
Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells.
Haematologica
; 101(5): 626-33, 2016 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-26721894
6.
Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide.
Haematologica
; 100(2): 263-8, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25510242
7.
A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission.
Blood
; 120(22): 4317-23, 2012 Nov 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-23002117
8.
A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma.
Blood
; 120(22): 4324-33, 2012 Nov 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-23033266
9.
IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect.
Blood
; 118(24): 6387-91, 2011 Dec 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-22031859
10.
Population Pharmacokinetics of Monalizumab in Patients With Advanced Solid Tumors.
J Clin Pharmacol
; 63(7): 817-829, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36852723
11.
Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo.
Proc Natl Acad Sci U S A
; 106(31): 12879-84, 2009 Aug 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-19561305
12.
Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells.
Blood
; 114(13): 2667-77, 2009 Sep 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-19553639
13.
CD73-Mediated Immunosuppression Is Linked to a Specific Fibroblast Population That Paves the Way for New Therapy in Breast Cancer.
Cancers (Basel)
; 13(23)2021 Nov 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-34884993
14.
Expression of the HLA-C2-specific activating killer-cell Ig-like receptor KIR2DS1 on NK and T cells.
Clin Immunol
; 135(1): 26-32, 2010 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-20093094
15.
Targeting natural killer cells in solid tumors.
Cell Mol Immunol
; 16(5): 415-422, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30911118
16.
Monalizumab: inhibiting the novel immune checkpoint NKG2A.
J Immunother Cancer
; 7(1): 263, 2019 10 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-31623687
17.
Clinical analysis of human natural killer cells.
Methods Mol Biol
; 415: 291-300, 2008.
Artigo
em Inglês
| MEDLINE | ID: mdl-18370161
18.
A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies.
Oncotarget
; 9(25): 17675-17688, 2018 Apr 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29707140
19.
Roles, responsibilities and characteristics of lay community health workers involved in diabetes prevention programmes: A systematic review.
PLoS One
; 12(12): e0189069, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-29216263
20.
Kinetics of Cytotoxic Lymphocytes Reconstitution after Induction Chemotherapy in Elderly AML Patients Reveals Progressive Recovery of Normal Phenotypic and Functional Features in NK Cells.
Front Immunol
; 8: 64, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28210257